A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Phase of Trial: Phase III
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Cyclophosphamide; Lenalidomide; Melphalan; Thalidomide
- Indications Amyloidosis
- Focus Registrational; Therapeutic Use
- Acronyms TOURMALINE-AL1
- Sponsors Takeda Oncology
- 22 Mar 2017 Planned End Date changed from 1 Apr 2020 to 1 Sep 2018.
- 22 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2018.
- 17 Dec 2015 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020, according to ClinicalTrials.gov record.